Kurin, Inc. Announces Agreement with Intalere for Kurin Lock to impact contaminated blood cultures

Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that it has been awarded a contract by Intalere for the Kurin product line. Effective July 1, 2020 the new three-year agreement allows Intalere members to take advantage of special pricing and terms.

“An agreement with Intalere is another important accomplishment for Kurin,” said Bob Rogers, Inventor and CEO of Kurin. “Hospitals are under increasing pressure to quickly and accurately diagnose their patients. Intalere emphasizes best practices and patient outcomes and we share patient safety values by providing innovative solutions designed to address a common source of contaminated blood cultures and in doing so, reducing overall healthcare costs.”

Kurin’s revolutionary and disruptive approach automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as approximately one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection. Contaminated blood cultures also create a financial burden to hospitals by prolonging hospital stays.

About Kurin, Inc.

Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.